Position in ROIV
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$239,838
New position
Shares Held
6,777
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#347
of 494 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sagewood Asset Management LP holds $3,255,470 across 8 Biotechnology names. ROIV ranks #8 (7.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
5,420 | $614,411 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
892 | $556,197 | |
| 3 | RPRX |
Royalty Pharma plc
|
8,972 | $503,060 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
809 | $401,854 | |
| 5 | EXEL |
Exelixis, Inc.
|
6,664 | $362,588 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
5,750 | $329,015 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
3,175 | $248,507 | |
| 8 | ROIV |
Roivant Sciences Ltd.
This page
|
6,777 | $239,838 |
All Filings in ROIV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $239,838 | 6,777 | Shares | Sole | 2026-07-29 | |
| No filing history on record for this holder in this stock. | ||||||